Guilherme Nader Marta: Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open

Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn:

“Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open.

ctDNA is a strong prognostic factor in early breast cancer and its detection was associated with increased risk of recurrence and death. The association with worse outcomes was stronger when ctDNA was detected after treatment and by primary tumor-informed assays.

The mean lead time from ctDNA detection to overt recurrence was ~11 months.
ctDNA detection specificity for breast cancer recurrence was high (range 0.7 to 1.0) but sensitivity was lower (range 0.3 to 0.7).

Check it out.”

Source: Guilherme Nader Marta/LinkedIn